PMN

3.1402.18%
NR

Neil R. Cashman

Co-Founder, Co-Chairman of Scientific Advisory Board, Chief Scientific Officer & Director

Dr. Neil R. Cashman, M.D., is Co-Founder of ProMIS Neurosciences, Inc. (formerly known as Amorfix Life Sciences Ltd.) since January 2004 and has been its Chief Scientific Officer since May 31, 2004. Dr. Cashman serves as a Principal Investigator of the Center of Research in Neurodegenerative Diseases. He serves as Scientific Director of PrioNet Columbia. Dr. Cashman Co-Founded Caprion Pharmaceuticals, Inc., in 1998 and served as its Scientific Advisor. He serves as the Director of the UBC ALS Centre. He is a neurologist-neuroscientist and a recognized expert in neurodegeneration and Neuro Immunology. His special areas of work are the amyloid encephalopathies, such as the prion illnesses and Alzheimer's disease and motor neuron diseases, including amyotrophic lateral sclerosis and post-polio syndrome. Dr. Cashman trained at University of Massachusetts Medical School, Children's Hospital of San Francisco, Hôpital Necker (France) and University of Chicago. He joined the McGill Neurology and Immunology faculties in 1986 and accepted the Diener Professorship of Neurodegenerative Diseases at the University of Toronto Department of Medicine (Neurology) in 1998. He is recognized worldwide as one of the principal leading research scientists and experts pioneering the emerging fields of protein misfolding as well as prion diagnostic and therapeutic development. Dr. Cashman has been Chairman and Member of Scientific Advisory Board of ProMIS Neurosciences, Inc. (formerly known as Amorfix Life Sciences Ltd.) since January 2007. He served as the Chairman of ProMIS Neurosciences, Inc. until June 2014. He served as an Interim Chairman of ProMIS Neurosciences, Inc. since October 2012. He served as the Diener (endowed) Chairman of Neurodegenerative Diseases. He has been Director of the ALS Clinic of the Vancouver General Hospital in British Columbia since 2005. He had been Director of ProMIS Neurosciences, Inc. (formerly known as Amorfix Life Sciences Ltd.) since June 9, 2010 and serves as its Non Independent Director. He served as a Member of Scientific Advisory Board at Prothena Corporation plc. Dr. Cashman served as a Director of ProMIS Neurosciences, Inc. (formerly known as Amorfix Life Sciences Ltd.) from September 21, 2005 to January 09, 2007. Dr. Cashman joined the ProMIS Neurosciences, Inc. on May 31, 2004. He served as Director of the Neuromuscular Clinic of Sunnybrook and Women's Hospital. Beginning in 2005, he serves as Professor of the University of British Columbia and has been named as the Canada Research Chair in Neurodegeneration and Protein Misfolding Diseases. Dr. Cashman served as a Director Professor of the University of Toronto from 1998 to 2005. In 2000, Dr. Cashman was awarded the Jonas Salk Prize for biomedical research. Dr. Cashman earned a Bachelor of Arts degree in Physics from Bowdoin College and a Medical Degree from the University of Massachusetts Medical School. Dr. Cashman served his residency in neurology with the University of Chicago Hospitals & Clinics.

Positions